Laboratorio Reig Jofre : 2018 09 17 - Transactions within the shares buyback program (PDF)
September 17, 2018 at 02:43 pm
Share
CNMV Edison, 4 28006 Madrid
In accordance with the Article 228 of Royal Legislative Decree 4/2015, dated 23 October, which enacts the consolidated text of the Securities Market Act, and in relation to the Shares Buyback Temporary Program reported on Relevant Fact of June 25, 2018 with registration number 268269, LABORATORIO REIG JOFRE SA ("Reig Jofre" or "the Company"), informs about the purchases in the week of September 10, 2018.
SUMARY OF TRANSACTIONS
DATE
SHARES
PRICE
CASH
14/09/2018
96
2,600
249,60
13/09/2018
600
2,650
1.590,00
10/09/2018
1.500
2,580
3.870,06
TOTAL
2.196
2,600
5.709,66
Adolf Rousaud
Secretary of the Board of Directors
Barcelona, September 17, 2018
ANNEX 1
Detail of transactions between September 10 and September 14, 2018
DATE
SHARES
PRICE
CASH
14/09/2018
96
2,600
249,60
13/09/2018
600
2,650
1.590,00
10/09/2018
48
2,540
121,92
10/09/2018
100
2,580
258,00
10/09/2018
250
2,560
640,00
10/09/2018
502
2,570
1.290,14
10/09/2018
600
2,600
1.560,00
TOTAL
2.196
2,600
5.709,66
Attachments
Original document
Permalink
Disclaimer
Laboratorio Reig Jofre SA published this content on 17 September 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 17 September 2018 13:42:08 UTC
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Companyâs activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.